載入...
The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis
OBJECTIVE: Secukinumab, a new treatment agent, selectively neutralizes interleukin (IL)-17A. It is used in the treatment of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis. It is known that the agents used in the treatment of rheumatic diseases have effects on hematological par...
Na minha lista:
| 發表在: | Eur J Rheumatol |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Medical Research and Education Association
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7574766/ https://ncbi.nlm.nih.gov/pubmed/32910771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/eurjrheum.2020.20109 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|